BIOA Should I Buy

BTIG initiated coverage of BioAge Labs with a Buy rating and $40 price target. BioAge is a clinical-stage biopharmaceutical company focused on treating disease related to human aging, the analyst tells investors in a research note. The firm says the company mines human datasets to identify proteins and genetic elements whose trajectories in early adulthood predict lifelong outcomes. It has a four-year cash runway with catalysts for BGE-102 in the second half of 2026 and for BGE-105 in mid-2027, BTIG notes. The firm believes BioAge's lead program in cardiovascular risk "seems biologically de-risked" based on readouts linking reductions in systemic inflammation to improved outcomes.